Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice

Bibliography

• FELMINGHAM D, GRÜNEBERG RN: A multicenter collaborative study of the antimicrobial susceptibility of community-acquired, lower respiratory tract pathogens 1992 – 1993: the Alexander Project. J. Antimicrob. Chemother. (1996) 38(Suppl. A):1-57.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, JONES RN, DOERN GV et al.: Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob. Agents Chemother. (1998) 42:1762-1770.
   PubMed Web of Science ®Google Scholar
• TURNER PJ, GREENHALGH JM, EDWARDS JR et al.: The MYSTIC (meropenem yearly susceptibility test information collection) programme. Int. J. Antimicrob. Agents (1999) 13:117-125.
   PubMed Web of Science ®Google Scholar
• PATERSON DL, ROSSI F, BAQUERO F et al.: In vitro susceptibility of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). J. Antimicrob. Chemother. (2005) 55:965-973.
   PubMed Web of Science ®Google Scholar
• RAMPHAL R, AMBROSE PG: Extended-spectrum β-lactamases and outcomes: current data. Clin. Inf. Dis. (2006) 42:164-172.
   PubMed Web of Science ®Google Scholar
• PATERSON DL: ‘Collateral damage’ from cephalosporin or quinolone antibiotic therapy. Clin. Inf. Dis. (2004) 38(Suppl. 4):341-345.
   PubMed Web of Science ®Google Scholar
• LIVERMORE DM: Minimising antibiotic resistance. Lancet Infect. Dis. (2005) 5:450-459.
   PubMed Web of Science ®Google Scholar
• BONFIGLIO G, RUSSO G, NICOLETTI G: Recent developments in carbapenems. Expert. Opin. Invest. Drugs (2002) 11:529-544.
   PubMed Web of Science ®Google Scholar
• ODENHOLT I: Ertapenem: a new carbapenem. Expert Opin. Investig. Drugs (2001) 10(Suppl. 2):23-28.
   Google Scholar
• CUNHA BA: Ertapenem. A review of its microbiologic, pharmacokinetic and clinical aspects. Drugs Today (2002) 38:195-213.
   PubMed Web of Science ®Google Scholar
• SHAH PM, ISAACS RD: Ertapenem, the first of a new group of carbapenems. J. Antimicrob. Chemother. (2003) 52:538-542.
   PubMed Web of Science ®Google Scholar
• LIVERMORE DM, SEFTON AM, SCOTT GM: Properties and potential of ertapenem. J. Antimicrob. Chemother. (2003) 52:331-344.
   PubMed Web of Science ®Google Scholar
• ZHANEL GG, JOHANSON C, EMBIL JM et al.: Ertapenem: review of a new carbapenem. Expert Rev. Anti Infect. Ther. (2005) 3:23-39.
   PubMedGoogle Scholar
• KEATING GM, PERRY CM: Ertapenem: a review of its use in the treatment of bacterial infections. Drugs (2005) 65:2151-2178.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN EJ: Treatment of complicated community-acquired infections with ertapenem, the first group 1 carbapenem. Introduction. J. Antimicrob. Chemother. (2004) 53(Suppl. 2):5-6.
   Web of Science ®Google Scholar
• HAMMOND ML: Ertapenem: a group 1 carbapenem with distinct antibacterial and pharmacological properties. J. Antimicrob. Chemother. (2004) 53(Suppl. 2):7-9.
   Web of Science ®Google Scholar
• KOHLER J, DORSO KL, YOUNG K et al.: In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum β-lactamase- and extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates. Antimicrob. Agents Chemother. (1999) 43:1170-1176.
   PubMed Web of Science ®Google Scholar
• SUMITA Y, FUKUKASAWA M, OKUDA T: Comparison of two carbapenems, SM-7338 and imipenem: affinities for penicillin-binding proteins and morphological changes. J. Antibiot. (1990) 43:314-320.
   PubMed Web of Science ®Google Scholar
• FRIEDLAND I, MIXSON LA, MAJUMDAR A et al.: In vitro activity of ertapenem against common clinical isolates in relation to human pharmacokinetics. J. Chemother. (2002) 14:483-491.
   PubMed Web of Science ®Google Scholar
• PANKUCH GA, DAVIES TA, JACOBS MR et al.: Antipneumococcal activity of ertapenem (MK-0826) compared to those of other agents. Antimicrob. Agents Chemother. (2002) 46:42-46.
   PubMed Web of Science ®Google Scholar
• HICKS PS, PELAK B, WOOD GL et al.: Comparative in vitro activity of ertapenem against bacterial pathogens isolated from patients with lower respiratory tract infections. Clin. Microbiol. Infect. (2002) 8:753-757.
   PubMed Web of Science ®Google Scholar
• HILLIARD NJ, JOHNSON CN, ARMSTRONG SH et al.: In vitro activity of ertapenem (MK-0826) against multi-drug resistant Streptococcus pneumoniae compared with 13 other antimicrobials. Int. J. Antimicrob. Agents (2002) 20:136-140.
   PubMed Web of Science ®Google Scholar
• PELAK BA, WOODS GL, TEPPLER H et al.: Comparative in-vitro activities of ertapenem against aerobic bacterial pathogens isolated from patients with complicated intra-abdominal infections. J. Chemother. (2002) 14:227-233.
   PubMed Web of Science ®Google Scholar
• PELAK BA, BARTIZAL K, WOODS GL et al.: Comparative in vitro activities of ertapenem against aerobic and facultative bacterial pathogens from patients with complicated skin and skin-structure infections. Diagn. Microbiol. Infect. Dis. (2002) 43:129-133.
   PubMed Web of Science ®Google Scholar
• PELAK BA, CITRON DM, MOTYL M et al.: Comparative in vitro activities of ertapenem against bacterial pathogens from patients with acute pelvic infection. J. Antimicrob. Chemother. (2002) 50:735-741.
   PubMed Web of Science ®Google Scholar
• FUCHS PC, BARRY AL, BROWN SD: In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers. Antimicrob. Agents Chemother. (2001) 45:1915-1918.
   PubMed Web of Science ®Google Scholar
• ROLSTON KV, LE BLANC BM, STREETER H et al.: In vitro activity of ertapenem against bacterial isolates from cancer patients. Diagn. Microbiol. Infect. Dis. (2002) 43:219-223.
   PubMed Web of Science ®Google Scholar
• LIVERMORE DM, CARTER MW, BAGEL S et al.: In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia. Antimicrob. Agents Chemother. (2001) 45:1860-1867.
   PubMed Web of Science ®Google Scholar
• FUCHS PC, BARRY AL, BROWN SD: In vitro antimicrobial activities of a carbapenem, MK-0826 (L-7949, 345) and provisional interpretative criteria for disc tests. J. Antimicrob. Chemother. (1999) 43:703-706.
   PubMed Web of Science ®Google Scholar
• REYNOLDS R, POTZ N, COLMAN M et al.: Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme. J. Antimicrob. Chemother. (2004) 53:1018-1032.
   PubMed Web of Science ®Google Scholar
• JONES RN, HUYNH HK, BIEDENBACH DJ et al.: Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J. Antimicrob. Chemother. (2004) 54:144-154.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN EJ, CITRON DM, MERRIAM VC et al.: Comparative in vitro activities of ertapenem and 11 other antimicrobial agents against aerobic and anaerobic pathogens isolated from skin and soft tissue animal and human bite wound infections. J. Antimicrob. Chemother. (2001) 48:641-651.
   PubMed Web of Science ®Google Scholar
• JONES RN: In vitro evaluation of ertapenem (MK-0826), a long-acting carbapenem, tested against selected resistant strains. J. Chemother. (2001) 13:363-376.
   PubMed Web of Science ®Google Scholar
• GE Y, WIKLER MA, SAHM DF et al.: In vitro antimicrobial activity of doripenem, a new carbapenem. Antimicrob. Agents Chemother. (2004) 48:1384-1396.
   PubMed Web of Science ®Google Scholar
• LIVERMOORE DM, ALEXANDER S, MARSDEN B et al.: Activity of ertapenem against Neisseria gonorrhoeae. J. Antimicrob. Chemother. (2004) 53:280-281.
   Google Scholar
• ALHAMBRA A, CUADROS JA, CACHO J et al.: In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics. J. Antimicrob. Chemother. (2004) 53:1090-1094.
   PubMed Web of Science ®Google Scholar
• ALDRIDGE KE: Ertapenem (MK-0826), a new carbapenem: comparative in vitro activity against clinically significant anaerobes. Diagn. Microbiol. Infect. Dis. (2002) 43:181-186.
   Google Scholar
• GOLDSTEIN EJ, CITRON DM, MERRIAM VC et al.: Comparative in vitro activities of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections. Antimicrob. Agents Chemother. (2000) 44:2389-2394.
   PubMed Web of Science ®Google Scholar
• BETRIU C, SANCHEZ A, PALAU ML et al.: In vitro activities of MK-0826 and 16 other antimicrobials against Bacteroides fragilis group strains. Antimicrob. Agents Chemother. (2001) 45:2372-2374.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN EJ, CITRON DM, MERRIAM VC et al.: General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin- and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillin-tazobactam. Clin. Infect. Dis. (2002) 35:119-125.
   Google Scholar
• GOLDSTEIN EJ, CITRON DM, MERRIAM VC et al.: Comparative in vitro activities of ertapenem (MK-0826) against 469 less frequently identified anaerobes isolated from human infections. Antimicrob. Agents Chemother. (2002) 46:1136-1140.
   PubMed Web of Science ®Google Scholar
• HOELLMAN DB, KELLY LM, CREDITO K et al.: In vitro antianaerobic activity of ertapenem (MK-0826) compared with seven other compounds. Antimicrob. Agents Chemother. (2002) 46:220-224.
   PubMed Web of Science ®Google Scholar
• WEXLER HM, MOLITORIS D, FINEGOLD SM: In vitro activities of MK-0826 (L-749, 345) against 363 strains of anaerobic bacteria. Antimicrob. Agents Chemother. (2000) 44:2222-2224.
   PubMed Web of Science ®Google Scholar
• WEXLER HM: In vitro activity of ertapenem: review of recent studies. J. Antimicrob. Chemother. (2004) 53(Suppl. 2):11-21.
   Web of Science ®Google Scholar
• PATERSON DL: Resistance in gram negative bacteria: Enterobacteriaceae. Am. J. Med. (2006) 119(Suppl. 1):20-28.
   PubMed Web of Science ®Google Scholar
• ODENHOLT I, LOWDIN E, CARS O: In vitro pharmacodynamic studies of L-749,345 in comparison with imipenem and ceftriaxone against gram-positive and gram-negative bacteria. Antimicrob. Agents Chemother. (1998) 42:2365-2370.
   PubMed Web of Science ®Google Scholar
• COTTAGNOUD P, PFISTER M, COTTAGNOUD M: Activities of ertapenem, a new long-acting carbapenem, against penicillin-sensitive or resistant Pneumococci in experimental meningitis. Antimicrob. Agents Chemother. (2003) 47:1943-1947.
   PubMed Web of Science ®Google Scholar
• CHOW JW, SHLAES DM: Imipenem resistance associated with the loss of a 40 kDa outer membrane protein in Enterobacter aerogenes. J. Antimicrob. Chemother. (1991) 28:499-504.
   PubMed Web of Science ®Google Scholar
• BORNET C, DAVIN-REGLI A, BOSI C et al.: Imipenem resistance of Enterobacter aerogenes mediated by outer membrane permeability. J. Clin. Microbiol. (2000) 38:1048-1052.
   PubMed Web of Science ®Google Scholar
• POIREL L, HERITIER C, TOLUN V et al.: Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob. Agents Chemother. (2004) 48:15-22.
   PubMed Web of Science ®Google Scholar
• LINCOPAN N, MC CULLOCH JA, REINERT C et al.: First isolation of metallo-β-lactamase-producing multiresistent Klebsiella pneumoniae from a patient in Brazil. J. Clin. Microbiol. (2005) 43:516-519.
   PubMed Web of Science ®Google Scholar
• GIAKKOUPI P, XANTHAKI A, KANELOPOULOU M et al.: VIM-1 metallo-β-lactamase-producing Klebsiella pneumoniae strains in Greek hospitals. J. Clin. Microbiol. (2003) 41:3893-3896.
   PubMed Web of Science ®Google Scholar
• YAN JJ, KO WC, TSAI SH et al.: Outbreak of infection with multidrug-resistant Klebsiella pneumoniae carrying bla(IMP-8) in a university medical center in Taiwan. J. Clin. Microbiol. (2001) 39:4433-4439.
   PubMed Web of Science ®Google Scholar
• YIGIT H, QUEENAN AM, ANDERSON GJ et al.: Novel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob. Agents Chemother. (2001) 45:1151-1161.
   PubMed Web of Science ®Google Scholar
• SMITH MOLAND E, HANSON ND, HERRERA VL et al.: Plasmid-mediated, carbapenem-hydrolyzing β-lactamase, KPC-2 in Klebsiella pneumoniae isolates. J. Antimicrob. Chemother. (2003) 51:711-714.
   PubMed Web of Science ®Google Scholar
• WOODFORD N, TIERNO JR PM, YOUNG K et al.: Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A β-lactamase, KPC-3, in a New York Medical Center. Antimicrob. Agents Chemother. (2004) 48:4793-4799.
   PubMed Web of Science ®Google Scholar
• BRATU S, LANDMAN D, HAAG R et al.: Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City a new threat to our antibiotic armamentarium. Arch. Intern. Med. (2005) 165:1430-1435.
   PubMed Web of Science ®Google Scholar
• BRATU S, TOLANEY P, KARUMUDI U et al.: Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY molecular epidemiology and in vitro activity of polymyxin B and other agents. J. Antimicrob. Chemother. (2005) 56:128-132.
   PubMed Web of Science ®Google Scholar
• BRATU S, LANDMAN D, ALAM M et al.: Detecting of KPC carbapenem-hydrolyzing enzymes in Enterobacter spp. from Brooklyn, New York. Antimicrob. Agents Chemother. (2005) 49:776-778.
   PubMed Web of Science ®Google Scholar
• MIRIAGOU V, TZOUVELEKIS LS, ROSSITER S et al.: Imipenem resistance in a Salmonella clinical strain due to plasmid-mediated class a carbapenemase KPC-2. Antimicrob. Agents Chemother. (2003) 47:1297-1300.
   PubMed Web of Science ®Google Scholar
• NIX DE, MAJUMDAR AK, DINUBILE MJ: Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians. J. Antimicrob. Chemother. (2004) 53(Suppl. 2):23-28.
   PubMedGoogle Scholar
• MAJUMDAR AK, MUSSON DG, BIRK KL et al.: Pharmacokinetics of ertapenem in healthy young volunteers. Antimicrob. Agents Chemother. (2002) 46:3506-3511.
   PubMed Web of Science ®Google Scholar
• WONG BK, SAHLY Y, MISTRY G et al.: Comparative disposition of [14C]ertapenem, a novel carbapenem antibiotic, in rat, monkey and man. Xenobiotica (2004) 34:379-389.
   PubMed Web of Science ®Google Scholar
• MUSSON DG, MAJUMDAR AK, HOLLAND S et al.: Pharmacokinetics of total and unbound ertapenem in healthy elderly subjects. Antimicrob. Agents Chemother. (2004) 48:521-524.
   PubMed Web of Science ®Google Scholar
• MUSSON DG, MAJUMDAR AK, BIRK K et al.: Pharmacokinetics of intramuscularly administered ertapenem. Antimicrob. Agents Chemother. (2003) 47:1732-1735.
   PubMed Web of Science ®Google Scholar
• PLETZ MWR, RAU M, BULITTA J et al.: Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers. Antimicrob. Agents Chemother. (2004) 48:3765-3772.
   PubMed Web of Science ®Google Scholar
• BURKHARDT O, KUMAR V, KATTERWE D et al.: Ertapenem in critically ill patients with early-onset VAP: pharmacokinetics with special consideration on the free drug concentration. J. Antimicrob. Chemother. In press.
   Google Scholar
• LAETHEM T, DE LEPELEIRE I, MCCREA J et al.: Tissue penetration by ertapenem, a parenteral carbapenem administered once-daily, in suction-induced skin blister fluid in healthy young volunteers. Antimicrob. Agents Chemother. (2003) 47:1439-1442.
   PubMed Web of Science ®Google Scholar
• BURKHARDT O, BRUNNER M, SCHMIDT S et al.: Penetration of ertapenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers measured by in vivo microdialysis. J. Antimicrob. Chemother. (2006) 58:632-638.
   PubMed Web of Science ®Google Scholar
• BURKHARDT O, MAJCHER-PESZYNSKA J, BORNER K et al.: Penetration of ertapenem into different pulmonary compartments of patients undergoing lung surgery. J. Clin. Pharmacol. (2005) 45:659-665.
   PubMed Web of Science ®Google Scholar
• BURKHARDT O, MAJCHER-PESZYNSKA J, BORNER K et al.: Penetration of ertapenem into different pulmonary compartments of patients undergoing lung surgery. Clin. Microbiol. Infect. (2005) 11(Suppl. 2):275.
   Google Scholar
• WITTAU M, WAGNER E, KAEVER V et al.: Intra-abdominal tissue concentration of ertapenem. J. Antimicrob. Chemother. (2006) 57:312-316.
   PubMed Web of Science ®Google Scholar
• MERCK & CO., INC: Invanz® (ERTAPENEM SODIUM) prescribing information. Merck & Co., Inc., Whitehouse Station (NJ) USA (2006).
   Google Scholar
• CHEN M, NAFZIGER AN, DRUSANO GL et al.: Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults. Antimicrob. Agents Chemother. (2006) 50:1222-1227.
   PubMed Web of Science ®Google Scholar
• HOLLAND SD, MAJUMDAR AK, MUSSON DG et al.: Pharmacokinetics of ertapenem in renal insufficiency (RI). Clin. Pharmacol. Ther. (2001) 69:16.
   Google Scholar
• MISTRY GC, MAJUMDAR AK, SWAN S et al.: Pharmacokinetics of ertapenem in patients with varying degrees of renal insufficiency and in patients on hemodialysis. J. Clin. Pharmacol. (2006) 46:1128-1138.
   PubMed Web of Science ®Google Scholar
• KUMAR V, BURKHARDT O, PLETZ M et al.: Comparison of pharmacodynamic target attainment of ertapenem in healthy volunteers and intensive care unit patients using Monte Carlo simulations. AAPS J. (2006) 8(Suppl. 2):3378.
   Google Scholar
• LISTER PD, BLACK J: Pharmacodynamics of Ertapenem, imipenem, cefepime and ceftriaxone against Escherichia coli and Klebsiella pneumoniae producing extended-spectrum β-lactamases (ESBL) and plasma-encoded AmpC cephalosporinases. Clin. Infect. Dis. (2001) 33:1185.
   Google Scholar
• XUAN D, BANEVICIUS M, CAPITANO B et al.: Pharmacodynamic assessment of ertapenem (MK-0826) against Streptococcus pneumoniae in a murine neutropenic thigh infection model. Antimicrob. Agents Chemother. (2002) 46:2990-2995.
   PubMed Web of Science ®Google Scholar
• MAGLIO D, BANEVICIUS MA, SUTHERLAND et al.: Pharmacodynamic profile of ertapenem against Klebsiella pneumoniae and Escherichia coli in a murine tigh model. Antimicrob. Agents Chemother. (2005) 49:276-280.
   PubMed Web of Science ®Google Scholar
• SCHUCK EL, DERENDORF H: Pharmacokinetic/pharmacodynamic evaluation of anti-infective agents. Expert Rev. Anti. Infect. Ther. (2005) 3:361-373.
   PubMedGoogle Scholar
• CRAIG WA: Pharmacodynamics of antimicrobials: general concepts and applications. In: Antimicrobial Pharmacodynamics in Theory and Clinical Practice. Nightingale C, Marakawa T, Ambrose PG (Eds). Marcel-Dekker, New York (2002):1-22.
   Google Scholar
• CRAIG WA: Pharmacokinetic/ pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. (1998) 26:1-12.
   PubMed Web of Science ®Google Scholar
• MOUTON JW, TOUZW DJ, HORREVORTS AM et al.: Comparative pharmacokinetics of the carbapenems: clinical implications. Clin Pharmacokinet (2000) 39:185-201.
   PubMed Web of Science ®Google Scholar
• FRIEDLAND I, MAJUMDAR A, MOTYL M et al.: Ertapenem is highly active against common clinical bacterial pathogens. Clin. Microbiol. Infect. (2002) 8(Suppl. 1):268.
   Google Scholar
• LIU P, DERENDORF H: Antimicrobial tissue concentrations. Infect. Dis. Clin. North Am. (2003) 17:599-613.
   PubMed Web of Science ®Google Scholar
• PEA F, VIALE P, FURLANUT M: Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin. Pharmacokinet. (2005) 44:1009-1034.
   PubMed Web of Science ®Google Scholar
• MCQUADE MS, VAN NOSTRAND V, SCHARITER J et al.: Stability and compatibility of reconstituted ertapenem with commonly used IV infusion and coinfusion solutions. Am. J. Health Syst. Pharm. (2004) 61:38-45.
   PubMed Web of Science ®Google Scholar
• SOLOMKIN JS, YELLIN AE, ROTSTEIN OD et al.: Ertapenem versus piperacillin/tazobactam in the treatment of complicated intra-abdominal infections: results of a double-blind, randomized comparative phase III trial. Ann. Surg. (2003) 237:235-245.
   PubMed Web of Science ®Google Scholar
• YELLIN AE, HASSETT JM, FERNANDEZ A et al.: Ertapenem monotherapy versus combination therapy with ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections in adults. Int. J. Antimicrob. Agents (2002) 20:165-173.
   PubMed Web of Science ®Google Scholar
• DE LA PENA AS, ASPERGER W, KÖCKERLING F et al.: Efficacy and safety of ertapenem versus piperacillin/tazobactam for the treatment of intra-abdominal infections requiring surgical intervention. J. Gastrointest. Surg. (2006) 10:567-574.
   PubMed Web of Science ®Google Scholar
• TOMERA KM, BURDMANN EA, REYNA OG et al.: Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind multi-center study. Antimicrob. Agents Chemother. (2002) 46:2895-2900.
   PubMed Web of Science ®Google Scholar
• JIMENEZ-CRUZ F, JASOVICH A, CAJIGAS J et al.: A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults. Urology (2002) 60:16-22.
   PubMed Web of Science ®Google Scholar
• ROY S, HIGAREDA I, ANGEL-MULLER E et al.: Ertapenem once-a-day versus piperacillin/tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multi-center, randomized, double-blind study. Infect. Dis. Obstet. Gynecol. (2003) 11:27-37.
   PubMedGoogle Scholar
• VETTER N, CAMBRONERO-HERNANDEZ E, ROHLF J et al.: A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia. Clin. Ther. (2002) 24:1770-1785.
   PubMed Web of Science ®Google Scholar
• ORTIZ-RUIZ G, CABALLERO-LOPEZ J, FRIEDLAND IR et al.: A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults. Clin. Infect. Dis. (2002) 34:1076-1083.
   PubMed Web of Science ®Google Scholar
• ORTIZ-RUIZ G, VETTER N, ISAACS R et al.: Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicenter randomized, double-blind studies. J. Antimicrob Chemother. (2004) 53(Suppl. 2):59-66.
   Web of Science ®Google Scholar
• WOODS GL, ISAACS RD, MC CARROLL KA et al.: Ertapenem therapy for community-acquired pneumonia in the elderly. J. Am. Geriatr. Soc. (2003) 51:1526-1532.
   PubMed Web of Science ®Google Scholar
• FRIEDLAND IR, MCCARROLL KA, DINUBILE MJ et al.: Ertapenem as initial antimicrobial monotherapy for patients with chronic obstructive pulmonary disease hospitalized with typical community-acquired pneumonia. Pulm. Pharmacol. Ther. (2004) 17:199-203.
   PubMed Web of Science ®Google Scholar
• GRAHAM DR, LUCASTI C, MALAFAIA O et al.: Ertapenem once-daily versus piperacillin/tazobactam four-times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multi-center study. Clin. Inf. Dis. (2002) 34:1560-1568.
   Google Scholar
• GESSER RM, MC CARROL KA, WOODS GL: Evaluation of outpatient treatment with ertapenem in a double blind controlled clinical trial of complicated skin/skin structure infections. J. Infect. (2004) 48:32-38.
   PubMed Web of Science ®Google Scholar
• GESSER RM, MC CARROL KA, WOODS GL: Efficacy of ertapenem against methicillin-susceptible Staphylococcus aureus in complicated skin/skin structure infections: results of a double-blind clinical trial versus piperacillin/tazobactam. Int. J. Antimicrob. Agents (2004) 23:235-239.
   PubMed Web of Science ®Google Scholar
• LIPSKY BA, ARMSTRONG DG, CITRON DM et al.: Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomized, controlled, double-blind, multi-center trial. Lancet (2005) 366:1695-1703.
   PubMed Web of Science ®Google Scholar
• GESSER RM, MC CARROL KA, TEPPLER H et al.: Efficacy of ertapenem in the treatment of serious infections caused by Enterobacteriaceae: analysis of pooled clinical trial data. J. Antimicrob. Chemother. (2003) 51:1253-1260.
   PubMed Web of Science ®Google Scholar
• TELLADO J, WOODS GL, GESSER RM et al.: Ertapenem versus piperacillin/tazobactam for treatment of mixed anaerobic complicated intra-abdominal, complicated skin and skin-structure, and acute pelvic infections. Surg. Infect. (2002) 3:303-314.
   PubMedGoogle Scholar
• SOLOMKIN J, TEPPLER H, GRAHAM DR et al.: Treatment of polymicrobial infections: post hoc analysis of three trials comparing ertapenem and piperacillin/tazobactam. J. Antimicrob. Chemother. (2004) 53(Suppl. 2):51-57.
   Web of Science ®Google Scholar
• ARGUEDAS A, WANG J, SNYDER T et al.: Safety and efficacy in a double-blind study of ertapenem versus ceftriaxone in pediatric patients with complicated urinary tract infections, community acquired pneumonia, or skin and soft tissue infections. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2005).
   Google Scholar
• JOHNSON J, YELLIN A, HIGAREDA I et al.: Safety and efficacy in an open-label study of ertapenem versus ticarcillin/clavulanate in pediatric patients with complicated intra-abdominal infections or acute pelvic infections. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA (2005).
   Google Scholar
• TEPPLER H, GESSER RM, FRIEDLAND IR et al.: Safety and tolerability of ertapenem. J. Antimicrob. Chemother. (2004) 53(Suppl. 2):75-81.
   Web of Science ®Google Scholar
• LEGUA P, LEMA J, MOLL J et al.: Safety and local tolerability of intramuscularly administered ertapenem diluted with lidocaine: a prospective, randomized, double-blind study versus intramuscular ceftriaxone. Clin. Ther. (2002) 24:434-444.
   PubMed Web of Science ®Google Scholar